Stage III Cutaneous Melanoma AJCC v7 Active Not Recruiting Phase 2 Trials for Dabrafenib (DB08912)

IndicationStatusPhase
DBCOND0091046 (Stage III Cutaneous Melanoma AJCC v7)Active Not Recruiting2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT02910700
Nivolumab With Trametinib and Dabrafenib, or Encorafenib and Binimetinib in Treating Patients With BRAF Mutated Metastatic or Unresectable Stage III-IV MelanomaTreatment
NCT02196181
Dabrafenib and Trametinib for the Treatment of Patients With Stage III-IV BRAF Mutant Melanoma That Cannot Be Removed by SurgeryTreatment